Jork von Reden
Director/Board Member bei PROTEO, INC.
Profil
Jork von Reden currently works at Proteo, Inc., as Director from 2018, CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun, as Managing Director from 2016, and Wind Energy Trust Sp zoo, as Managing Director from 2009.
Mr. von Reden received his graduate degree from Technical University of Berlin.
Aktive Positionen von Jork von Reden
Unternehmen | Position | Beginn |
---|---|---|
PROTEO, INC. | Director/Board Member | 15.11.2018 |
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun Miscellaneous Commercial ServicesCommercial Services CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun provides business consulting and investment services. The private company is based in Berlin, Germany. Jork von Reden has been the CEO of the German company since 2016. | Chief Executive Officer | 01.01.2016 |
Wind Energy Trust Sp zoo | Chief Executive Officer | 01.01.2009 |
Ausbildung von Jork von Reden
Technical University of Berlin | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Proteo, Inc.
Proteo, Inc. Pharmaceuticals: MajorHealth Technology Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The firm focuses on the development of anti-inflammatory treatments for rare diseases. Its proprietary product Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands. The company's product is intended for the treatment of post-surgery damage to tissue, pulmonary hypertension, serious injuries caused by accidents, cardiac infarction, and other diseases, as well as for the complications resulting from organ transplantation. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded by Oliver Wiedow and Birge Bargmann on December 18, 1992 and is headquartered in Irvine, CA. | Health Technology |
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun Miscellaneous Commercial ServicesCommercial Services CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun provides business consulting and investment services. The private company is based in Berlin, Germany. Jork von Reden has been the CEO of the German company since 2016. | Commercial Services |
Wind Energy Trust Sp zoo |